Last reviewed · How we verify

budesonide/formoterol Turbuhaler 320/9µg

AstraZeneca · FDA-approved active Small molecule

budesonide/formoterol Turbuhaler 320/9µg is a Inhaled corticosteroid/long-acting beta-2 agonist combination Small molecule drug developed by AstraZeneca. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors.

Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic namebudesonide/formoterol Turbuhaler 320/9µg
SponsorAstraZeneca
Drug classInhaled corticosteroid/long-acting beta-2 agonist combination
TargetGlucocorticoid receptor; beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhaseFDA-approved

Mechanism of action

Budesonide is an inhaled corticosteroid that suppresses inflammatory mediators and immune cell recruitment in the airways. Formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, providing sustained bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about budesonide/formoterol Turbuhaler 320/9µg

What is budesonide/formoterol Turbuhaler 320/9µg?

budesonide/formoterol Turbuhaler 320/9µg is a Inhaled corticosteroid/long-acting beta-2 agonist combination drug developed by AstraZeneca, indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does budesonide/formoterol Turbuhaler 320/9µg work?

Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors.

What is budesonide/formoterol Turbuhaler 320/9µg used for?

budesonide/formoterol Turbuhaler 320/9µg is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes budesonide/formoterol Turbuhaler 320/9µg?

budesonide/formoterol Turbuhaler 320/9µg is developed and marketed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What drug class is budesonide/formoterol Turbuhaler 320/9µg in?

budesonide/formoterol Turbuhaler 320/9µg belongs to the Inhaled corticosteroid/long-acting beta-2 agonist combination class. See all Inhaled corticosteroid/long-acting beta-2 agonist combination drugs at /class/inhaled-corticosteroid-long-acting-beta-2-agonist-combination.

What development phase is budesonide/formoterol Turbuhaler 320/9µg in?

budesonide/formoterol Turbuhaler 320/9µg is FDA-approved (marketed).

What are the side effects of budesonide/formoterol Turbuhaler 320/9µg?

Common side effects of budesonide/formoterol Turbuhaler 320/9µg include Tremor, Headache, Palpitations, Oral candidiasis, Nervousness.

What does budesonide/formoterol Turbuhaler 320/9µg target?

budesonide/formoterol Turbuhaler 320/9µg targets Glucocorticoid receptor; beta-2 adrenergic receptor and is a Inhaled corticosteroid/long-acting beta-2 agonist combination.

Related